{{medref|date=September 2014}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 470474605
| IUPAC_name = [(2''R'')-3,3-Dimethyl-4,4,7-trioxy-4λ<sup>6</sup>-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxymethyl(2''R'')-6-{[(2''S'')-2-amino-2-phenyl-acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
| image = Sultamicillin.svg
<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|sultamicillin}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_CA = <!--                             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration = Oral
<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 76497-13-7
| ATC_prefix = J01
| ATC_suffix = CR04
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 506110
| PubChem = 444022
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 392048
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 65DT0ML581
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05972
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 51770
<!--Chemical data-->
| C=25 | H=30 | N=4 | O=9 | S=2
| molecular_weight = 594.659 g/mol
| smiles = O=C(OCOC(=O)[C@@H]2N1C(=O)C[C@H]1S(=O)(=O)C2(C)C)[C@@H]4N5C(=O)[C@@H](NC(=O)[C@@H](c3ccccc3)N)[C@H]5SC4(C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C25H30N4O9S2/c1-24(2)17(29-20(32)16(21(29)39-24)27-19(31)15(26)12-8-6-5-7-9-12)22(33)37-11-38-23(34)18-25(3,4)40(35,36)14-10-13(30)28(14)18/h5-9,14-18,21H,10-11,26H2,1-4H3,(H,27,31)/t14-,15-,16-,17+,18+,21-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OPYGFNJSCUDTBT-PMLPCWDUSA-N
}}

'''Sultamicillin''' is an oral form of the antibiotic combination ([[codrug]] or mutual [[prodrug]]) [[ampicillin/sulbactam]]. It contains [[ester]]ified [[ampicillin]] and [[sulbactam]] and is marketed under a number of trade names, e. g. '''Unasyn''' from [[Pfizer]].

The pharmacokinetic properties of sultamicillin are improved compared to a combination of ampicillin and sulbactam.  Sultamicillin increases the absorption and decreases the chances of [[diarrhea]] and [[dysentery]]. The inclusion of sulbactam extends ampicillin's spectrum of action to [[beta-lactamase]] producing strains of bacteria. Oral sulbactam with parenteral form provides a regimen of continuous sulbactam therapy throughout the treatment, resulting in better clinical results.

==Chemical evaluation==
Sultamicillin is a mutual prodrug of ampicillin and sulbactam. Ampicillin, a [[semi-synthetic]] orally active broad spectrum antibiotic, is linked via a [[methylene group]] with a beta-lactamase inhibitor. Sultamicillin is chemically oxymethyl penicillinate sulfone ester of ampicillin.

==Mechanism of action==
After absorption, sultamicillin releases ampicillin and sulbactam into the system, so all the antibacterial efficacy of sultamicillin is due to ampicillin and sulbactam. Ampicillin exerts antibacterial activity against sensitive organisms by inhibiting biosynthesis of cell wall mucopeptide where as sulbactam irreversibly inhibits most important beta-lactamases that occur in resistant strains.

==Indications==
[[Indication (medicine)|Indication]]s for sultamicillin include:

* Skin and soft tissue infections - [[furuncle]]s, [[carbuncle]]s, [[cellulitis]], [[paronychia]], [[impetigo contagiosa]], [[diabetic foot ulcer]]s and abscesses caused by ''[[Staphylococcus aureus]]'' and ''[[Streptococcus pyogenes]]''.
* [[Upper respiratory tract infection]]s - [[pharyngitis]] and [[tonsillitis]] caused by ''[[S. pyogenes]]'' and ''S. aureus''. Acute and chronic sinusitis caused by ''S. aureus'', ''[[S. pneumoniae]]'', ''[[H. influenzae]]'' and ''S. progenies''. [[otitis media]], particularly suppurative otis media, with or without [[mastoiditis]] antrum.
* [[Lower respiratory tract infection]]s - [[bacterial pneumonia]]s, [[bronchitis]], [[bronchiectasis]] caused by ''S. pneumoniae'', ''H. influenzae'', ''Staphylococcus aureus'' and ''S. progenies''. Acute exacerbations of [[COPD]].
* [[Urinary tract infection]]s - [[pyelonephritis]], [[cystitis]] caused by ''[[Escherichia coli]]'', ''[[Proteus mirabilis]]'', ''[[Klebsiella]]'', ''[[Enterobacter]]'' and ''Staphylococcus aureus''.
* Surgical infections - prophylaxis and treatment of surgical site infections, peri-operative prophylaxis in orthopaedic and cardiovascular surgery.
* Gynecological infections - Caused by beta-lactamase producing strains of ''E. coli'' and ''[[Bacteroides]]'' sp. (including ''[[B. fragilis]]'').
* Infections of the [[gastrointestinal tract]] - Bacterial [[esophagitis]], treatment of ''[[H. pylori]]'' infections as a part of MDT in ulcer management.

==References==
{{nofootnotes|date=September 2014}}
* {{cite journal | doi =10.2174/1389557043487547 | pmid = 14754446| year = 2004| author1 = Singh| first1 = G.S.| title = Beta-lactams in the new millennium. Part-II: Cephems, oxacephems, penams and sulbactam| journal = Mini Reviews in Medicinal Chemistry| volume = 4| issue = 1| pages = 93–109}}

{{Cell wall disruptive antibiotics}}

[[Category:Penicillins]]
[[Category:Codrugs]]